iBrands Corp. (OTC PINK: IBRC) "PUREST CBD" Product Line includes the following: "Purest CBD juice dropper"; "Purest CBD Spray"; "Purest CBD Honey" and best seller, "Purest CBD Cartridge Disposable Devise." iBrands Corp. (OTC PINK: IBRC) brand "PUREST CBD" has a competitive advantage to the Cannabainoid marketplace due to its formation from unique extraction technique and its optimum level of purity. 

Cannabidiol (CBD) and Tetrahydrocannabinol (THC) are the two major components of the cannabis plant. CBD has been shown to have great medicinal value. Compared to THC, CBD is essentially non-psychoactive, and is considered to have a wider scope of medicinal applications. CBD is arguably one of the most important components found in the cannabis plant. Possibly the universe. 

According to a 2013 review published in the British Journal of Clinical Pharmacology, studies have found CBD to possess the following medical properties: Medical Properties of CBD Effects Antiemetic Combats nausea and vomiting Anticonvulsant Combats seizure activity Antipsychotic Combats psychosis disorders Anti-inflammatory Combats inflammatory disorders Anti-oxidant Combats neurodegenerative disorders Anti-tumoral/Anti-cancer Combats tumor and cancer cells Anxiolytic/Anti-depressant Combats anxiety and depression disorders.

Some Ways to Use CBD: vaporize, eat, topical, tincture, capsule, drink, juice, transdemal patch, smoke, dab.

Benefits of CBD: Anti-Anxiety, Anti-Inflammatory, Anti-Depressant, Anti-Oxidant, Anti-Pain, Free Radical Scavenger, Cardiac Protestant, Neuro Protectant, Promotes Glucose Tolerance, Reduces Blood Sugar Levels, Kills or Slows Bacteria Growth, Cancer Cell Regulator, Non-Habit Forming, Protects from Nervous System Degeneration, Promotes Bone Growth, Reduces Immune System Issues & Analgesic Benefits.

Conditions Treated by CBD: AIDS/ HIV, Alcoholism, ALS, Alzheimer's, Anorexia, Anxiety, Autoimmune Disorders, Cardiovascular Disease, Cancer Adjutant Therapy, Chronic Nausea & Vomiting, Chron's, Depression, Diabetes, Glaucoma, Hepatitis C, Lupus, Lyme Disease, Migraines, Mood Disorders, Multiple Sclerosis, Muscle Spasms, Small Intestine Contractions, Pain & Inflammation, Parkinsons, Psychosis, Post Traumatic Stress Disorder, Psoriasis, Rheumatoid Arthritis, Schizophrenia, Seizure Disorders, Convulsions, Tinnitus.

About iBrands Corporation, Inc. - A holding company that acquires and operates niche market brands having unique market positions within sectors that demonstrate return on investment potential. Business partnerships throughout the United States, Canada, Mexico, South America, and Europe provide our brands many markets to expand into and produce consistently high growth rates for the next decade. www.iBrandscorporation

Safe Harbor Statement: 

This press release may contain forward looking statements and or observations which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues as well as any payment of dividends on our stock, statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties include but not limited to information as contained within the Company's most current quarterly reports, annual reports, and or other such filings as may be accessed through the OTCBB website. Furthermore, the Company disclaims any intention or obligation to update or revise any such forward looking statements, whether as a result of new information, future events, or otherwise. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new product lines noting there is no assurance that we will generate enough revenues to offset those costs. Additional product offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the variables as associated with the general business channel we are operating in, the impact of which cannot be predicted at this time including risks as associated with our product and recent FDA pronouncements. Additionally, our 1-A registration statement will generate additional free trading shares to the marketplace at a pre-determined price which may impact our share pricing within the OTC marketplace in a manner that we cannot predict.